Patents by Inventor Shanchun GUO

Shanchun GUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of androgen receptor signaling
    Patent number: 11708381
    Abstract: The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 25, 2023
    Assignee: XAVIER UNIVERSITY OF LOUISIANA
    Inventors: Guangdi Wang, Jiawang Liu, Shilong Zheng, Shanchun Guo
  • INHIBITORS OF ANDROGEN RECEPTOR SIGNALING
    Publication number: 20210284663
    Abstract: The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 16, 2021
    Inventors: Guangdi WANG, Jiawang LIU, Shilong ZHENG, Shanchun GUO
  • Boronic derivatives of hydroxamates as anticancer agents
    Patent number: 11046715
    Abstract: The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamates as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: June 29, 2021
    Assignee: Xavier University of Louisiana
    Inventors: Guangdi Wang, Shilong Zheng, Jiawang Liu, Qiu Zhong, Shanchun Guo
  • BORONIC DERIVATIVES OF HYDROXAMATES AS ANTICANCER AGENTS
    Publication number: 20200181175
    Abstract: The present disclosure relates to boronic derivatives of hydroxamate compounds, methods for making the same, methods for use as a monotherapy or in combination with one or more other therapeutic agents, for treatment of proliferative diseases such as cancer. The present disclosure also teaches the utilization of said boronic derivatives of hydroxamates as epigenetic therapy medications with enhanced bioavailability, lower-toxicity, and longer-lasting efficacy.
    Type: Application
    Filed: November 27, 2017
    Publication date: June 11, 2020
    Inventors: Guangdi WANG, Shilong ZHENG, Jiawang LIU, Qiu ZHONG, Shanchun GUO
  • SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS (SERDS)
    Publication number: 20190233442
    Abstract: The present disclosure relates to orally bioavailable selective estrogen receptor down-regulators (SERDs) and the synthesis of the same. Further, the present disclosure teaches the utilization of the orally bioavailable selective estrogen receptor down-regulators (SERDs) in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 1, 2019
    Inventors: Guangdi WANG, Jiawang LIU, Shilong ZHENG, Qui ZHONG, Shanchun GUO